Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

Description

Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.

Conditions

Endometriosis

Talk to us

Study Overview

On this page

Study Details

Study overview

Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.

Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis

Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

Condition
Endometriosis
Intervention / Treatment

-

Contacts and Locations

New Haven

The John B. Pierce Laboratory, New Haven, Connecticut, United States, 06519

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician \<10 years prior, and reported by the subject to the researchers)
  • * Tylenol if the subject has acute pain is allowed
  • * IUD contraceptive use (copper or levonogestrel) is allowed
  • * Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)
  • * Diabetes (HbA1C .6.5%)
  • * BP\>140/90
  • * Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)
  • * Pregnancy
  • * Breastfeeding
  • * Taking illicit and/or recreational drugs
  • * Abnormal liver function
  • * Rash, skin disease, disorders of pigmentation, known skin allergies
  • * Diagnosed or suspected metabolic or cardiovascular disease
  • * Persistent unexplained elevations of serum transaminases
  • * Known allergy to latex or investigative substances

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Penn State University,

Study Record Dates

2026-12-31